Company Updates | VARUNÉ Labs Scotland

Owned editorial

Insights and development updates.

Evidence-led analysis, evidence-controlled development records and open diligence questions from VARUNÉ Labs Scotland. These pages are owned editorial, not independent press coverage. Sources provide context, not endorsement or access.

Company news

Owned editorial from VARUNÉ Labs. Plans are not approvals, discussions are not partnerships and concept imagery is not an operating record.

Company newsField diligence record

Varun Sharma visits the wider AMIDS area during early location diligence

The photograph records presence in the wider area only. It does not establish parcel access, site control, approval, partnership or construction.

Read the controlled visit record
Company newsDevelopment update

VARUNÉ Labs Scotland focuses detailed site diligence on the AMIDS and Glasgow Airport corridor

The corridor is the preferred Scottish area for the next stage of location work, with no binding commitment.

Read update
Company newsOwned editorial

Varun Sharma sets an evidence-led vision for VARUNÉ Labs Scotland

The founder sets out a partner-first, evidence-first and reversible approach to the proposed campus programme.

Read company news

VARUNÉ insights

Read the reasoning behind the campus concept.

Luxury licence governance

Luxury beauty licensing: who owns the brand, formula, factory and risk?

A responsibility map for brand rights, formulation, manufacturing, distribution, creative control and cosmetic regulation, with no VARUNÉ product or launch announcement.

Read insight
Analysis

What makes a science campus credible?

An evidence-led analysis of the infrastructure, operating model and governance that make a science campus credible.

Read insight
Location diligence

Why Glasgow City Region is being evaluated for a proposed medicines campus

Why VARUNÉ Labs is evaluating the AMIDS and Glasgow Airport corridor, and which facts must be proven before any site decision.

Read insight
Medicines development

Why formulation and analytical science should shape medicines infrastructure

How formulation, analytical understanding, quality risk management and life-cycle learning can inform future medicines infrastructure.

Read insight
Intelligent systems

Designing responsible AI and robotics for future medicines operations

A governance-first view of how future AI, robotics and connected laboratory systems could support medicines operations.

Read insight